Showing 2961-2970 of 2973 results for "".
DermWireTV: PCA to Space Station; ASDS Pandemic Data; LaRoche-Posay, GW Partnership
https://practicaldermatology.com/topics/practice-management/dermwiretv-pca-to-space-station-asds-pandemic-data-laroche-posay-gw-partnership/20059/The "Great Resignation" forcing some dermatology practices to operate with reduced staffing is just one of the lingering impacts of the COVID-19 pandemic on practices, according to results of a survey by the American Society for Dermatologic Surgery. PCA skin is sending the first-ever private sectorNew eRelevance Services, Cosmetic Bootcamp Updates, Leo & AID Partnership
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-erelevance-services-cosmetic-bootcamp-updates-leo-aid-partnership/18291/eRelevance has launched a suite of 4 services intended to support aesthetic practices in optimizing their marketing strategies to capture, convert, and retain patients. CEO Bob Fabbio discusses. Aesthetic education takes center stage at Cosmetic Boot Camp in Aspen. The meeting is open only to boardWhy We Should Be PRO Patients With CKD-Associated Pruritus
https://practicaldermatology.com/programs/cme/why-we-should-be-pro-patients-with-ckd-associated-pruritus/14968/Our experts offer tips to effectively use Patient-Reported Outcome Measures (PROMs) in clinical practice to improve health outcomes in patients with CKD-aP.Rhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhatigan-to-merz-moc-dissatisfaction-syneron-candela-sale/18485/Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of SyDermWireTV: Noble Educates on Self-Injection; AAD and DEF Meeting Updates
https://practicaldermatology.com/topics/practice-management/dermwiretv-noble-educates-on-self-injection-aad-and-def-meeting-updates/19645/Participants in a study by the company Noble show that the vast majority of patients—92%—would prefer to bring home a training device to practice with prior to starting self-injection. Noble creates trainers for autoinjectors intended to increase patient confidence and autonomy with self-managed treDermWireTV: Updates from ASDS: EBDs, Injectables, Scars, DEI
https://practicaldermatology.com/topics/practice-management/dermwiretv-updates-from-asds-ebds-injectables-scars-dei/20029/The annual meeting of the American Society for Dermatology Surgery (ASDS) brings together top dermatologists to share their expertise. This year’s virtual meeting offered a look at a range of new and emerging treatments and some updates on existing options, including insights from Jeanine B. Downie,Sunscreen Ratings, Restylane Lyft for Hands, NPF, SCF News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-ratings-restylane-lyft-for-hands-npf-scf-news/18305/Both Consumer Reports and the Environmental Working Group have issued sunscreen rankings, and while some products shine, many products may underperform. FDA issued warnings to several companies illegally marketing dietary supplements that make unproven drug claims about protecting consumers from sunTaking the Patient-Centered Approach to Mycophenolate Risk Mitigation
https://practicaldermatology.com/programs/cme/taking-the-patient-centered-approach-to-mycophenolate-risk-mitigation-mycophenolate-risk-mitigation/16628/Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation.DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latesDermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.